CD274 and non-small cell lung carcinoma: Advanced NSCLC patients with PD-L1–positive (PD-L1 TPS ≥1%) were enrolled in KEYNOTE-001 (NCT01295827), KEYNOTE-010 (NCT01905657), KEYNOTE-024 (NCT02142738), and KEYNOTE-042 (NCT02220894) and then assigned to single pembrolizumab or docetaxel groups.